Skip to main content
Caplight Logo









Fesarius Therapeutics

Fesarius Therapeutics

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.fesariustherapeutics.com/

Last Round

Series A

Jun 10, 2026

Total Funding Raised

$28.63M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Fesarius Therapeutics is a bioregenerative medical technology company that develops solutions for wound care, reconstructive surgery, and regenerative medicine.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

advanced wound careregenerative medicinedermal regeneration templatecollagen hydrogeltissue engineeringskin substitutetissue scaffoldfull-thickness skin lossbioregenerative technologymedical deviceskin graft alternativereconstructive surgerybiomaterialFDA 510(k) clearanceburn treatmentchronic ulcer treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fesarius Therapeutics Comparables

Compare Fesarius Therapeutics with similar companies based on industry and business-model similarity.

Fesarius Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Omeza
81%
MedSkin Solutions Dr. Suwelack
79%
Aroa Biosurgery
78%

Fesarius Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 10, 2026
Convertible DebtNov 1, 2023
GrantAug 16, 2023
GrantAug 8, 2023

Key People

Founding team and executive leadership

Tom Roueche

President and Chief Executive Officer

Executive Team

Fesarius Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 19, 2026

    Grew 20% QoQ, from 15 to 18 employees.

  • Jun 10, 2026

    $20M round led by Jefferson Life Sciences.

Fesarius Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Fesarius Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Fesarius Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range18
Year Founded2015
Last FundingJun 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?